St Jude Medical's Angio-Seal STS Plus vascular closure device
This article was originally published in Clinica
Executive Summary
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for the Angio-Seal STS Plus vascular closure device, a product developed by St Jude Medical to help seal catheterisation sites. It is approved for both percutaneous peripheral and cardiac interventional catheterisation procedures, and enables physicians to seal the femoral artery punctures made during the surgery. The device incorporates a self-tightening suture, which St Paul, Minnesota-based St Jude claims is a significant advantage over its Angio-Seal Millennium vascular closure platform, which has been used in Japanese cath labs since 2004. The Ministry has also granted reimbursement approval for the device.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.